Cipla inches up on entering into partnership with Premier Medical Corporation

16 Dec 2020 Evaluate

Cipla is currently trading at Rs. 783.35, up by 1.65 points or 0.21% from its previous closing of Rs. 781.70 on the BSE.

The scrip opened at Rs. 787.00 and has touched a high and low of Rs. 788.50 and Rs. 782.50 respectively. So far 31303 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 829.00 on 13-Oct-2020 and a 52 week low of Rs. 356.75 on 13-Mar-2020.

Last one week high and low of the scrip stood at Rs. 798.00 and Rs. 753.00 respectively. The current market cap of the company is Rs. 63039.89 crore.

The promoters holding in the company stood at 36.70%, while Institutions and Non-Institutions held 39.82% and 23.48% respectively.

Cipla has entered into partnership with the Premier Medical Corporation for commercialization of the rapid antigen test kits for COVID-19 in India. The company will commence supply from this week.

This is Cipla’s second launch in the diagnostics space after Elifast: SARS CoV-2 IgG ELISA Test Kit. In this collaboration, Cipla will be responsible for the marketing and distribution of the Rapid Antigen Detection Test for the qualitative detection of SARS-CoV-2 antigen that will be manufactured by Premier Medical Corporation.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla Share Price

1423.85 17.90 (1.27%)
16-May-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1532.20
Dr. Reddys Lab 5820.00
Cipla 1423.85
Zydus Lifesciences 1008.15
Lupin 1659.15
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.